Biocon Biologics Secures European Commission Approval for Ustekinumab Biosimilar, Expanding Global Reach

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has received European Commission approval for YESINTEK®, its ustekinumab biosimilar, on February 18, 2025. This approval follows the positive recommendation from the European Medicines Agency's CHMP in December 2024. YESINTEK® is indicated for treating plaque psoriasis in adults and children, as well as psoriatic arthritis and Crohn's disease in adults. This milestone expands Biocon's biosimilar portfolio in Europe, complementing recent approvals in the US and Japan. The company's strategic global expansion in the biosimilars market is expected to strengthen its immunology franchise and provide affordable treatment options for patients with autoimmune diseases across Europe.

 

Sources: Biocon Limited, NSE Archives, Express Pharma